Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:AEX CVE:BOR NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsBORBorder PetroleumC$0.01-33.3%C$0.01C$0.01▼C$0.04C$637KN/A236,078 shs25,000 shsPHARPharming Group$12.36+0.9%$15.19$9.54▼$21.34$872.51M-0.0422,535 shs8,861 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%BORBorder Petroleum0.00%0.00%0.00%0.00%0.00%PHARPharming Group-0.33%-9.73%-27.92%-22.68%+5.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsBORBorder PetroleumC$0.01-33.3%C$0.01C$0.01▼C$0.04C$637KN/A236,078 shs25,000 shsPHARPharming Group$12.36+0.9%$15.19$9.54▼$21.34$872.51M-0.0422,535 shs8,861 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%BORBorder Petroleum0.00%0.00%0.00%0.00%0.00%PHARPharming Group-0.33%-9.73%-27.92%-22.68%+5.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEXAEX Gold 0.00N/AN/AN/ABORBorder Petroleum 0.00N/AN/AN/APHARPharming Group 2.40Hold$38.33213.18% UpsideCurrent Analyst Ratings BreakdownLatest TLOU, PHAR, BOR, and AEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.003/30/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/24/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.003/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)3/13/2026PHARPharming Group OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$42.00 ➝ $41.003/12/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$37.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEXAEX GoldN/AN/AC$0.13 per share4.59C$0.21 per shareN/ABORBorder PetroleumC$1.31M0.49N/AN/AC($0.02) per share-0.63PHARPharming Group$376.13M2.30$0.20 per share61.23$3.95 per share3.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEXAEX GoldN/A-C$0.14N/AN/AN/AN/AN/AN/AN/ABORBorder PetroleumN/A-C$0.02N/AN/AN/AN/AN/AN/AN/APHARPharming Group$2.85M$0.1676.5018.83N/A3.30%4.64%2.55%7/30/2026 (Estimated)Latest TLOU, PHAR, BOR, and AEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEXAEX GoldN/AN/AN/AN/AN/ABORBorder PetroleumN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEXAEX Gold2.0919.9019.77BORBorder PetroleumN/A0.600.60PHARPharming Group0.352.632.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEXAEX GoldN/ABORBorder PetroleumN/APHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipAEXAEX GoldN/ABORBorder PetroleumN/APHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEXAEX GoldN/A177.10 millionN/ANot OptionableBORBorder PetroleumN/A63.69 millionN/ANot OptionablePHARPharming Group28070.62 million69.16 millionNot OptionableJOG, AEX, PHAR, and BOR HeadlinesRecent News About These CompaniesPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSJune 4 at 2:03 AM | globenewswire.comPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkJune 2 at 2:22 AM | finance.yahoo.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by AnalystsMay 30, 2026 | americanbankingnews.comPharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | finanznachrichten.dePharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | manilatimes.netMPharming Group N.V. (PHAR) Shareholder/Analyst Call - SlideshowMay 28, 2026 | seekingalpha.comPharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndromeMay 26, 2026 | pharmabiz.comPEuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionMay 22, 2026 | markets.businessinsider.comPharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their ModelsMay 10, 2026 | finance.yahoo.comPharming Group (PHAR) Gets a Buy from Canaccord GenuityMay 9, 2026 | theglobeandmail.comPharming Group (NASDAQ:PHAR) Lowered to Hold Rating by Wall Street ZenMay 9, 2026 | marketbeat.comPharming Group Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comPharming Group (NASDAQ:PHAR) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026May 7, 2026 | markets.businessinsider.comPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersMay 7, 2026 | markets.businessinsider.comPharming Group N.V. (PHAR) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Gap Down After Earnings MissMay 7, 2026 | marketbeat.comPharming Group N.V. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comPharming earnings in focus: Can rare disease growth offset Q1 dip?May 6, 2026 | investing.comPharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 6, 2026 | finance.yahoo.comPharming Group ADR PHGMay 5, 2026 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026JOG, AEX, PHAR, and BOR Company DescriptionsAEX Gold CVE:AEXC$0.62 -0.01 (-1.59%) As of 07/11/2022AEX Gold Inc. engages in the acquisition, exploration, and development of mineral properties in Greenland. It holds interests in licenses covering an area of 7,615.85 square kilometers located in South Greenland. The company was formerly known as Alopex Gold Inc. and changed its name to AEX Gold Inc. in June 2018. AEX Gold Inc. was incorporated in 2017 and is headquartered in Toronto, Canada.Border Petroleum CVE:BORC$0.01 -0.01 (-33.33%) As of 07/30/2018Border Petroleum Limited engages in the acquisition, exploration, development, and production of crude oil, natural gas and, natural gas liquids in the province of Alberta, Canada. The company holds working interests in 520 gross acres in the Norris area of central Alberta, as well as in five producing oil wells and one water disposal well; 9,647 gross acres in the Mulligan area; 3,170 gross acres in the Cherhill area of southwestern Alberta; and 11,070 gross acres in the Blueridge area. It also holds a non-operated interest in the Chip Lake property. The company is based in Calgary, Canada.Pharming Group NASDAQ:PHAR$12.36 +0.12 (+0.94%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker Ulta's Q1 Report Primes It for a Beauty of a Rebound Palo Alto Networks Accelerates Growth 31% on AI Demand How the Memory Shortage Is Crushing the Gaming Industry As AI Data Breaches Become More Common, This Cybersecurity ETF Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
